Why Medical Innovation Deserves a Place in Your Portfolio

How much is the healthcare industry really worth?

‍

When people are healthier there’s less strain on public health services. It’s a huge incentive for governments and health care providers to invest in innovative technology. The fewer sick people there are in hospitals, the more money there is to go around elsewhere.

‍

The healthcare industry is big business, and medical innovation has always been a lucrative sector for investors. It always will be, too, because as long as we’re still made from flesh and bone, there will always be a need for tech that takes away what ails us.

‍

According to Statista, revenue in the healthcare market is set to reach $57.86 billion in 2023. If predictions are correct, that could rise to $85.95 billion by 2027. And with the global population set to reach almost 10 billion by 2050, it’s not hard to see why we’re in need of serious and continued innovation. For investors, the healthcare industry presents one of the safest potential growth areas around, if you know where to look.

‍

‍

Illumina Inc.

Cambridge-based Illumina stands at the forefront of personalised medicine. Illumina develops and markets genomic sequencing technologies that enable researchers and healthcare professionals to analyse DNA and identify genetic variations.

‍

‍

Their technology has paved the way for precision medicine and has applications in cancer diagnostics, rare disease identification, and population health studies.

‍

Regeneron

With a 2022 revenue of $12.17 billion, US-based Regeneron pushes the boundaries of science to create medicine for people in need. From cardiovascular and infectious diseases, to oncology, neurology, and rare diseases, Regeneron has been innovating for over 30 years.

‍

‍

The company currently has dozens of treatments in its pipeline, including new treatments for cervical cancer and Alzheimer’s.

‍

Medical Cannabis (ETF available on NuWealth Standard)

We’re big fans of the medical cannabis and CBD industry. As we’ve mentioned before, medical cannabis is nothing new, and has been used as a pain reliever for centuries.

‍

It’s only in the past decade that CBD has really caught the attention of investors. The global CBD industry was valued at $6.4 billion in 2022. And the plant’s usage goes way beyond helping people to chill out.

‍

CBD and other types of medical cannabis have the potential to help millions of people suffering with Alzheimer’s, MS, epilepsy, and certain types of cancer.

‍

Medical Cannabis can make a lucrative and worthwhile addition to your investing portfolio. Our Medical Cannabis ETF, available on NuWealth Standard, is a great place to start.

‍